Zobrazeno 1 - 10
of 109
pro vyhledávání: '"Charles A. Schneider"'
Autor:
Charles J. Schneider, Michael Krainock, Allyson Koyen Malashevich, Meenakshi Malhotra, Perry Olshan, Paul R. Billings, Alexey Aleshin
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 2, Pp 849-853 (2021)
Immunotherapy (IO) has increasingly been demonstrated to provide therapeutic benefit to patients with metastatic colorectal cancer (mCRC). However, only a subset of mCRC tumors respond to IO. Monitoring response with tumor biomarkers like carcinoembr
Externí odkaz:
https://doaj.org/article/718109250eb1486fa0b03794c8bc919a
Autor:
Nicole F. Laslett, SuJung Park, Gregory A. Masters, David D. Biggs, Charles J. Schneider, Jamal G. Misleh, Kathir Suppiah, Pamela S. Simpson, Stephen Grubbs, Timothy F. Wozniak, Michael Guarino
Publikováno v:
Cancer Medicine, Vol 7, Iss 7, Pp 2969-2973 (2018)
Abstract Lung cancer remains the leading cause of cancer death throughout the world. Despite new chemotherapeutic, immunomodulating and molecularly targeted agents, patients with locally advanced or metastatic disease still have a poor prognosis. Thi
Externí odkaz:
https://doaj.org/article/2297a7a08b024d68b2d231ee20dac90e
Autor:
William J. Chapin, Jacob E. Till, Wei-Ting Hwang, Jennifer R. Eads, Thomas B. Karasic, Peter J. O'Dwyer, Charles J. Schneider, Ursina R. Teitelbaum, Janae Romeo, Taylor A. Black, Theresa E. Christensen, Colleen Redlinger Tabery, Amanda Anderson, Megan Slade, Michael LaRiviere, Stephanie S. Yee, Kim A. Reiss, Mark H. O'Hara, Erica L. Carpenter
Publikováno v:
JCO precision oncology. 6
PURPOSE Pancreatic ductal adenocarcinoma (PDAC) is associated with a poor prognosis. Multianalyte signatures, including liquid biopsy and traditional clinical variables, have shown promise for improving prognostication in other solid tumors but have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69b5c3a9a69c1348cb58b0dfe0498373
https://pubmed.ncbi.nlm.nih.gov/35939771
https://pubmed.ncbi.nlm.nih.gov/35939771
Autor:
David M. Goldenberg, Robert M. Sharkey, William A. Wegener, Boyd Mudenda, Pius P. Maliakal, Serengulam V. Govindan, Wells A. Messersmith, Ronald Scheff, Kevin Kalinsky, Leena Gandhi, Tirrell Johnson, Allyson Ocean, Bryan J. Schneider, Charles J. Schneider, Jamal Misleh, Michael J. Guarino, W. Thomas Purcell, Gregory A. Masters, Ebenezer A. Kio, D. Ross Camidge, Alexander N. Starodub, Rebecca S. Heist, Jhanelle E. Gray
Purpose: We evaluated a Trop-2–targeting antibody conjugated with SN-38 in metastatic small cell lung cancer (mSCLC) patients.Experimental Design: Sacituzumab govitecan was studied in patients with pretreated (median, 2; range, 1–7) mSCLC who rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85d3221b48c4ae9f44d5518d04b2e195
https://doi.org/10.1158/1078-0432.c.6526244.v1
https://doi.org/10.1158/1078-0432.c.6526244.v1
Autor:
David M. Goldenberg, Robert M. Sharkey, William A. Wegener, Boyd Mudenda, Pius P. Maliakal, Serengulam V. Govindan, Wells A. Messersmith, Ronald Scheff, Kevin Kalinsky, Leena Gandhi, Tirrell Johnson, Allyson Ocean, Bryan J. Schneider, Charles J. Schneider, Jamal Misleh, Michael J. Guarino, W. Thomas Purcell, Gregory A. Masters, Ebenezer A. Kio, D. Ross Camidge, Alexander N. Starodub, Rebecca S. Heist, Jhanelle E. Gray
Immunohistology expression of Trop-2 vs response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39c28d7d0d017206cdcb8eeb9b98c5f6
https://doi.org/10.1158/1078-0432.22466114
https://doi.org/10.1158/1078-0432.22466114
Autor:
David M. Goldenberg, Robert M. Sharkey, William A. Wegener, Boyd Mudenda, Pius P. Maliakal, Serengulam V. Govindan, Wells A. Messersmith, Ronald Scheff, Kevin Kalinsky, Leena Gandhi, Tirrell Johnson, Allyson Ocean, Bryan J. Schneider, Charles J. Schneider, Jamal Misleh, Michael J. Guarino, W. Thomas Purcell, Gregory A. Masters, Ebenezer A. Kio, D. Ross Camidge, Alexander N. Starodub, Rebecca S. Heist, Jhanelle E. Gray
Evaluation of IHC staining vs best overall response in SCLC treated with 8 or 10 mg/kg starting dose of sacituzumab govitecan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b47b04cd98cbbe62d66c192352ea6bce
https://doi.org/10.1158/1078-0432.22466111
https://doi.org/10.1158/1078-0432.22466111
Autor:
Samuele Cannas, Jacob E. Till, Kristine Kim, Michael J. LaRiviere, Charles M. Vollmer, Jennifer R. Eads, Thomas B. Karasic, Peter J. O'Dwyer, Charles J. Schneider, Ursina R. Teitelbaum, Kim A. Reiss Binder, Mark H. O'Hara, Douglas T. Ross, Kim McGregor, Kirsten Bornemann-Kolatzki, Ekkehard Schütz, Julia Beck, Erica L. Carpenter
Publikováno v:
Cancer Research. 83:1043-1043
Introduction: In the setting of metastatic pancreatic adenocarcinoma (mPDAC), lower baseline plasma KRAS mutation levels have been associated with improved survival. While tissue-agnostic, plasma-based copy number instability (CNI) has been demonstra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d774849563b59bef85e5e0e61f86c0a8
https://doi.org/10.1158/1538-7445.am2023-1043
https://doi.org/10.1158/1538-7445.am2023-1043
Publikováno v:
The Oncologist
Background Companion diagnostic (CDx) testing for patients with advanced non‐small cell lung cancer (aNSCLC) identifies patients more likely to benefit from biomarker‐driven treatments. Methods Patients with nonsquamous cell (non‐Sq) aNSCLC fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f977cd9cb36e941d4346f28df289dc0
https://doi.org/10.1634/theoncologist.2019-0864
https://doi.org/10.1634/theoncologist.2019-0864
Autor:
Mark H. O'Hara, Adham S. Bear, Max M. Wattenberg, Ursina R. Teitelbaum, Kim A. Reiss, Thomas B. Karasic, Charles J. Schneider, Peter J. O'Dwyer, Edgar H. Ben-Josef, Andrzej P. Wojcieszynski, Amit H. Maity, Rosemarie H. Mick, Robert H. Vonderheide
Publikováno v:
Cancer Research. 82:A016-A016
Immune checkpoint inhibitors have limited clinical activity in pancreatic cancer. Based on preclinical data, we hypothesized that hypofractionated radiation may cooperate with dual checkpoint inhibition in patients (Rech AJ, et al, Cancer Research, 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0866eb77debc46444121d6f8806b5bb2
https://doi.org/10.1158/1538-7445.panca22-a016
https://doi.org/10.1158/1538-7445.panca22-a016
Autor:
Kim Anna Reiss, Rosemarie Mick, Ursina R. Teitelbaum, Mark H. O'Hara, Charles John Schneider, Ryan Campbell Massa, Thomas Benjamin Karasic, Chioma Onyiah, Mary Kate Gosselin, Alyssa Donze, Susan M. Domchek, Robert H. Vonderheide
Publikováno v:
Journal of Clinical Oncology. 40:4021-4021
4021 Background: Establishing alternatives to perpetual chemotherapy for pts with aPDAC has been proposed to address inevitable chemotherapy resistance and cumulative toxicity. Poly (ADP ribose) polymerase (PARP) inhibitors have shown clinical effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7573a78d12bbadac6d267c5e403a9e5
https://doi.org/10.1200/jco.2022.40.16_suppl.4021
https://doi.org/10.1200/jco.2022.40.16_suppl.4021